ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1156

Suppression Of Immune Responses and Joint Inflammation By Myeloid-Derived Suppressor Cells In a T Cell-Dependent Mouse Model Of Rheumatoid Arthritis

Katalin Mikecz1, Julia Kurko1, Timea Ocsko1, Andras Vida1, Beata Tryniszewska1, Tibor A. Rauch1, Joel A. Block2, Robert S. Katz3, Anjali Nair2, Carla R. Scanzello4 and Tibor T. Glant1, 1Orthopedic Surgery, Rush University Medical Center, Chicago, IL, 2Section of Rheumatology, Rush University Medical Center, Chicago, IL, 3Rush Medical College, Chicago, IL, 4Rheumatology, Rush University Medical Center, Chicago, IL

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Animal models, innate immunity, rheumatoid arthritis (RA) and synovial cells, synovial fluid, T cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Innate Immunity and Rheumatic Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of innate immune cells with immunosuppressive properties. We previously identified MDSCs in the synovial fluid (SF) of mice with proteoglycan-induced arthritis (PGIA), a T cell-dependent model of rheumatoid arthritis (RA). Although SF MDSCs potently inhibited antigen-specific T cell proliferation in vitro, they were not available in quantities necessary for testing their in vivo suppressive activity in PGIA. Using bone marrow (BM)-derived MDSCs, expanded in culture in the presence of growth factors, we sought to determine whether these cells could exert suppression on antigen-specific responses and arthritis severity upon their transfer to syngeneic mice with PGIA. An important additional goal of this study was to identify MDSCs in the SF of human patients with RA.

Methods: As reported previously, MDSCs with strong suppressor activity were successfully expanded from murine BM in vitro in the presence of GM-CSF, G-CSF, and IL-6. We used the adoptive transfer model of PGIA, in which spleen cells from arthritic wild type donors were injected with antigen (PG) into syngeneic SCID recipients. After the clinical signs of arthritis began to develop, the SCID mice were divided into groups with similar average disease scores. The control groups received a second injection of arthritic spleen cells and PG, while the experimental groups received the same plus MDSCs. Disease severity was monitored by visual scoring. Three weeks later, spleen cells from the SCID recipients were tested for antigen (PG)-specific proliferation, and sera were assayed for anti-PG antibody titers. Human SF and blood were obtained from consenting RA patients undergoing therapeutic joint aspiration. The phenotype of SF cells was determined by flow cytometry with antibodies to human MDSC-specific markers. The ability of RA SF MDSCs to suppress T cell proliferation was tested by culturing autologous blood mononuclear cells in the presence or absence of SF cells. T cell proliferation was induced via anti-CD3/CD28 antibodies or with Mitomycin C-treated allogeneic lymphocytes.

Results: Arthritis severity in SCID mice injected with BM MDSCs were significantly lower (mean score 3.5) than in control mice injected with spleen cells only (mean score 8.25) (n=10 mice/treatment). PG-specific T-cell responses and serum IgG1 type antibodies were also significantly reduced in the BM MDSC recipient groups. Regarding the human system, both granulocytic and monocytic MDSC-like cells were identified in SF samples (n=9) from RA patients. RA SF MDSCs suppressed the proliferation of autologous blood T cells ex vivo, although the inhibitory effects were not as strong as those in the murine system. Depletion of T cells from the RA SF cell population further improved the MDSC-mediated suppression of blood T cell proliferation.

Conclusion: Murine BM-derived MDSCs effectively suppress arthritis upon injection into SCID mice developing adoptively transferred PGIA. Cells with MDSC-like phenotype and immunosuppressive activity are also present in the SF of RA patients. Our results suggest that MDSCs could represent a novel therapeutic tool in RA.


Disclosure:

K. Mikecz,
None;

J. Kurko,
None;

T. Ocsko,
None;

A. Vida,
None;

B. Tryniszewska,
None;

T. A. Rauch,
None;

J. A. Block,

Ferring, Inc.,

5,

PL Pharma, Inc.,

9;

R. S. Katz,
None;

A. Nair,
None;

C. R. Scanzello,
None;

T. T. Glant,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/suppression-of-immune-responses-and-joint-inflammation-by-myeloid-derived-suppressor-cells-in-a-t-cell-dependent-mouse-model-of-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology